Blocking a specific protein to improve immune response against oral cancer
Targeted Arf1 inhibition to enhance immune response in oral cancer
This study is testing a new treatment for oral cancer that uses a special compound called AI10b to target a protein that helps cancer cells grow, with the hope of boosting the immune system's ability to fight the cancer while keeping healthy cells safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11035236 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for oral cancer by targeting a protein called ADP-ribosylation factor 1 (Arf1), which is often overactive in oral cancer cells. The approach involves using a novel compound, AI10b, that can inhibit Arf1 without harming normal cells. By blocking Arf1, the treatment aims to enhance the immune response against cancer cells, potentially leading to better outcomes for patients. The research will evaluate the effectiveness and safety of this compound in preclinical models before considering clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with oral cancer, particularly those with advanced stages of the disease.
Not a fit: Patients with oral cancer who have already received extensive treatment or those with other types of cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new targeted therapy that improves survival rates and quality of life for patients with oral cancer.
How similar studies have performed: While targeting Arf1 is a novel approach, similar strategies targeting other oncogenic pathways have shown promise in cancer treatment, indicating potential for success.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Teng, Yong — Emory University
- Study coordinator: Teng, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.